Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation

Transplantation Proceedings

Volumn 42, Issue 7, 2010, Pages 2572-2575

  Schleicher, C ^a   Palmes, D ^a   Utech, M ^a   Bonrath, E ^a   Senninger, N ^a   Schmidt, H ^a   Wolters, H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

ADULT; ANEMIA; ANKLE EDEMA; ARTICLE; CHOLANGITIS; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; INCISIONAL HERNIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77956460981     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.05.159     Document Type: Article

References (15)

1. A.O. Ojo, P.J. Held, and F.K. Port Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931
2. K.D. Fairbanks, J.A. Eustace, and D. Fine Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus Liver Transpl 9 2003 1079
3. S. Nair, J. Eason, and G. Loss Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients Liver Transpl 9 2003 126
4. E.Q. Sanchez, A.P. Martin, and T. Ikegami Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years Transplant Proc 37 2005 4416
5. A.H. Cotterell, R.A. Fisher, and A.L. King Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent Clin Transplant 16 suppl 7 2002 49
6. P. De Simone, H.J. Mestelaar, and L. Fischer Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial Liver Transpl 15 2009 1262
7. I. Bilbao, G. Sapisochin, and C. Dopazo Indications and management of everolimus after liver transplantation Transplant Proc 41 2009 2172
8. G. Levy, H. Schmidli, and J. Punch Safety, tolerability and efficacy of everolimus in de novo liver transplant recipients: 12 and 36 month results Liver Transpl 12 2006 1640
9. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31
10. P. De Simone, A. Precisi, and S. Petrucelli The impact of everolimus on renal function in maintenance liver transplantation Transplant Proc 41 2009 1300
11. G.W. Neff, M. Montalbano, and A.G. Tzakis Ten years of sirolimus in orthotopic liver transplant recipients Transplant Proc 35 suppl 3A 2003 209S
12. D. DuBay, R.J. Smith, and K.G. Qiu Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens Liver Transpl 14 2008 651
13. C.C. Rogers, S.R. Johnson, and D.A. Mandelbrot Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients [published online ahead of print July 28, 2009] Clin Transplant 23 2009 887
14. F. Di Benedetto, S. Di Sandro, and N. De Ruvo Immunosuppressive switch to sirolimus in renal dysfunction after liver transplantation Transplant Proc 41 2009 1297
15. J.M. Alamo, L. Barrera, and M.D. Casado Efficacy, tolerance and safety of mammalian target of rapamycin inhibitors as rescue immunosuppression in liver transplantation Transplant Proc 41 2009 2181